ROS-Responsive activatable photosensitizing agent for imaging and photodynamic therapy of activated macrophages

Theranostics

Volumn 4, Issue 1, 2014, Pages 1-11

  Kim, Hyunjin ^a   Kim, Youngmi ^b   Kim, In Hoo ^a   Kim, Kyungtae ^a   Choi, Yongdoo ^a  

^a National Cancer Center   (South Korea)

^b Dankook University   (South Korea)

Author keywords

Activatable; Macrophage; Photodynamic therapy.; Reactive oxygen species; Theranostics

Indexed keywords

CHLORIN E6; HYALURONIC ACID; NANOPARTICLE; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; THERANOSTIC NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CONCENTRATION (PARAMETERS); EXTRACELLULAR SPACE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; ILLUMINATION; IN VITRO STUDY; LIGHT INTENSITY; MACROPHAGE ACTIVATION; MOUSE; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; SKIN FIBROBLAST;

ACTIVATABLE; MACROPHAGE; PHOTODYNAMIC THERAPY.; REACTIVE OXYGEN SPECIES; THERANOSTICS;

CELL LINE; FIBROBLASTS; HUMANS; HYALURONIC ACID; MACROPHAGE ACTIVATION; MACROPHAGES; NANOPARTICLES; OPTICAL IMAGING; PEROXYNITROUS ACID; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; REACTIVE OXYGEN SPECIES; SPECTROSCOPY, NEAR-INFRARED;

EID: 84896706912     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7101     Document Type: Article

References (44)

1. Farb A, Burke AP, Tang AL Liang TY, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-63.
2. Virmani R, Kolodgie F, Burke A, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
3. Hellings WE, Peeters W, Moll FL, Pasterkamp G. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med 2007; 17: 162-71.
4. Cassells W, Hathorn B, David M, Krabach T, Vaughn WK, McAllister HA, Bearman G, Willerson JT. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet 1996; 347: 1447-51.
5. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JGS, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Nat Acad Sci USA 2007; 104: 961-6
6. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation 2007; 116: 1052-61.
7. McCarthy JR. Nanomedicine and cardiovascular disease. Curr Cardiovasc Imaging Rep 2010; 3: 42-9.
8. Dolmans DE, Dai Fukumura RKJ. Photodynamic therapy of cancer. Nat Rev Cancer 2003; 3: 380-7.
9. Waksman R, McEwan PE, Moore TI, Pakala R, Kologdie FD, Hellinga DG, Seabron RC, Rychnovsky SJ, Vasek J, Scott RW, Virmani R. PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression. J Am Coll Cardiol 2008; 52: 1024-32.
10. Peng C, Li Y, Liang H, Cheng J, Li Q, Sun X, Li Z, Wang F, Guo Y, Tian Z, Yang L, Tian Y, Zhang Z, Cao W. Detection and photodynamic therapy of inflamed atherosclerotic plaques in the carotid artery of rabbits. J Photochem Photobiol B 2011; 102: 26-31.
11. Kossodo S, LaMuraglia GM. Kossodo S, LaMuraglia GM. Clinical potential of photodynamic therapy in cardiovascular disorders. Am J Cardiovasc Drugs 2001; 1: 15-21.
12. Hsiang Y, Stonefield M, Bower RD, Fragoso M, Tsang V, Crespo MT, Lundkvist A. Assessing Photofrin uptake in atherosclerosis with a fluorescent probe: comparison with photography and tissue measurements. Lasers Surg Med 1993; 13: 271-8.
13. Hsiang YN, Crespo MT, Richter AM, Jain AK, Fragoso M, Levy JG. In vitro and in vivo uptake of benzoporphyrin derivative into human and miniswine atherosclerotic plaque. Photochem Photobiol 1993; 57: 670-4.
14. Litvack F, Grundfest WS, Forrester JS, Fishbein MC, Swan HJ, Corday E, Rider DM, McDermid IS, Pacala TJ, Laudenslager JB. Effects of hematoporphyrin derivative and photodynamic therapy on atherosclerotic rabbits. Am J Cardiol 1985; 56: 667-71.
15. Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung AC, Shunk KA, Chou TM, Popma J, Fitzgerald P, Carroll TE, Forer D, Adelman DC. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation 2003; 108: 1310-5.
16. Liu Q, Hamblin MR. Macrophage-targeted photodynamic therapy: Scavenger receptor expression and activation state. Int J Immunopathol Pharmacol 2005; 18: 391-402.
17. McCarthy JR, Jaffer FA, Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small 2006; 2: 983-7.
18. Tawakol A, Castano AP, Anatelli F, Bashian G, Stern J, Zahra T, Gad F, Chirico S, Ahmadi A, Fischman AJ, Muller JE, Hamblin MR. Photosensitizer delivery to vulnerable atherosclerotic plaque: comparison of macrophage-targeted conjugate versus free chlorin(e6). J Biomed Opt 2006; 11: 021008.
19. Kamat M, El-Boubbou K, Zhu DC, Lansdell T, Lu X, Li W, Huang X. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem 2010; 21: 2128-35.
20. McCarthy JR, Korngold E, Weissleder R, Jaffer FA. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 2010; 6: 2041-49.
21. Lovell JK, Liu TW, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. Chem Rev 2010; 110: 2839-57.
22. Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res 2006; 66: 7225-9.
23. Jang B, Park JY, Tung CH, Kim IH, Choi Y. Gold nanorod-photosensitizer complex for near-infrared fluorescence imaging and photodynamic/ photothermal therapy in vivo. ACS Nano 2011; 5: 1086-94.
24. Bae BC, Na K. Self-quenching polysaccharide-based nanogels of pullulan/ folate-photosensitizer conjugates for photodynamic therapy. Biomaterials 2010; 31: 6325-35.
25. Park W, Park SJ, Na K. The controlled photoactivity of nanoparticles derived from ionic interactions between a water soluble polymeric photosensitizer and polysaccharide quencher. Biomaterials 2011; 32: 8261-70.
26. Park SY, Baik HJ, Oh YT, Oh KT, Youn YS, Lee ES. A smart polysaccharide/ drug conjugate for photodynamic therapy. Angew Chem Int Ed 2011; 50: 1644-7.
27. Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, Leary JF, Park K, Yuk SH, Park JH, Choi K. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 2012; 33: 3980-9.
28. Jang B, Choi Y. Photosensitizer-conjugated gold nanorods for enzyme-activatable fluorescence imaging and photodynamic therapy. Theranostics 2012; 2: 190-7.
29. Cho Y, Choi Y. Graphene oxide-photosensitizer conjugate as a redox-responsive theranostic agent. Chem Commun 2012; 48: 9912-4.
30. Cho Y, Kim H, Choi Y. A graphene oxide-photosensitizer complex as an enzyme-activatable theranostic agent. Chem Commun 2013; 49: 1202-4.
31. Shon SM, Choi Y, Kim JY, Lee DK, Park JY, Schellingerhout D, Kim DE. Photodynamic therapy using a protease-mediated theranostic agent reduces cathepsin-B activity in mouse atheromata in vivo. Arterioscler Thromb Vasc Biol 2013; 33: 1360-5.
32. Bogdan C, Rollinghoff M, Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000; 12: 64-76.
33. Kohr MJ, Roof SR, Zweier JL, Ziolo MT. Modulation of myocardial contraction by peroxynitrite. Front Physiol 2012; 3: 468.
34. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, Green PS, McDonald TO, Brunzell J, Chait A, Oram JF, O'brien K, Geary RL, Heinecke JW. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004; 279: 42977-83.
35. Duan J, Kasper DL. Oxidative depolymerization of polysaccharides by reactive oxygen/nitrogen species. Glycobiology 2011; 21: 401-9.
36. Lee H, Lee K, Kim IK, Park TG. Fluorescent gold nanoprobe sensitive to intracellular reactive oxygen species. Adv Funct Mater 2009; 19: 1884-90.
37. Hamblin MR, Miller JL, Rizvi I. Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res 2001; 61: 7155-62.
38. Soltes L, Mendichi R, Kogan G, Schiller J, Stankovska M, Amhold J. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules 2006; 7: 659-68.
39. Kennett EC, Davies MJ. Degradation of matrix glycosminoglycans by peroxynitrite/ peroxynitrous acid: Evidence for a hydroxyl-radical-like mechanism. Free Radic Biol Med 2007; 42: 1278-89.
40. Li M, Rosenfeld L, Vilar RE, Cowman MK. Degradation of Hyaluronan by Peroxynitrite. Arch Biochem Biophys 1997; 341: 245-50.
41. Corsaro MM, Pietraforte D, Di Lorenzo AS, Minetti M, Marino G. Reaction of peroxynitrite with hyaluronan and related saccharides. Free Radic Res 2004; 38: 343-53.
42. Buttery LD, Sqringall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
43. Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci 2007; 80: 1921-43.
44. Bot PT, Pasterkamp G, Goumans MJ, Strijder C, Moll FL, de Vries JP, Pals ST, de Kleijn DP, Piek JJ, Hoefer IE. Hyaluronic acid metabolism is increased in unstable plaques. Eur J Clin Invest 2010; 40: 818-27.